Clinical Trials Logo

Marginal Zone Lymphoma clinical trials

View clinical trials related to Marginal Zone Lymphoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05934097 Withdrawn - Clinical trials for Mantle Cell Lymphoma

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Start date: December 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I study of FT596 in combination with two different schedules (standard or alternate) of R-CHOP in subjects with B-cell lymphoma who are previously untreated or have received no more than one prior line of treatment. The study will consist of a dose-escalation stage followed by a dose-expansion stage.

NCT ID: NCT04665115 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Start date: November 23, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effects of ibrutinib in treating patients with B-cell malignancies who are infected with COVID-19. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ibrutinib is a first in class Bruton tyrosine kinase inhibitor (BTKi), for the treatment of B-cell malignancies. This study is being done to determine if taking ibrutinib after contracting COVID-19 will make symptoms better or worse.

NCT ID: NCT04043845 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Start date: February 3, 2020
Phase: Phase 1
Study type: Interventional

This research is studying the safety of combining ibrutinib with the study drug LY3214996 for chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL).

NCT ID: NCT02623920 Withdrawn - Follicular Lymphoma Clinical Trials

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

S-BR
Start date: December 16, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well brentuximab vedotin, bendamustine, and rituximab work in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment. Monoclonal antibody-drug conjugates, such as brentuximab vedotin, use antibody to target chemotherapy in cancer cells. Drugs used in chemotherapy, such as bendamustine, work in different ways to kill cancer cells. Monoclonal antibodies, such as rituximab, kill the cancer cells directly, but also harness the immune system to kill the cancer cells. Adding brentuximab to rituximab may improve response rates in CD30 positive, CD20 positive Relapsed Refactory NHL.

NCT ID: NCT02576275 Withdrawn - Follicular Lymphoma Clinical Trials

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

Start date: December 2015
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of duvelisib in combination with bendamustine and rituximab (DBR) vs placebo in combination with bendamustine and rituximab (PBR) in subjects with previously-treated indolent non-Hodgkin lymphoma (iNHL).

NCT ID: NCT01460602 Withdrawn - Clinical trials for Mantle Cell Lymphoma

Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma

Start date: May 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2 Study of VELCADE (bortezomib), Nipent (pentostatin), and Rituxan (rituximab) (VNR) in Subjects with Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma.